Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 10/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249298 | 0.94 | WNT3A (0.47) | WNT3ASMN1; SMN2L3MBTL1RAB9APORCN | |
| SCHEMBL17243393 | 0.87 | WNT3A (0.48) | WNT3ASMN1; SMN2L3MBTL1RAB9APORCN | |
| SCHEMBL17243383 | 0.84 | L3MBTL1 (0.46) | WNT3ASMN1; SMN2L3MBTL1RAB9ACYP1A2 | |
| SCHEMBL248044 | 0.79 | WNT3A (0.49) | WNT3ASMN1; SMN2RAB9ACYP1A2CYP2C9 | |
| SCHEMBL248928 | 0.78 | KDM1A (0.52) | WNT3AL3MBTL1 | |
| SCHEMBL17243388 | 0.78 | WNT3A (0.52) | WNT3ASMN1; SMN2RAB9APORCNCYP1A2 | |
| SCHEMBL14802382 | 0.77 | HDAC1 (0.52) | WNT3ASMN1; SMN2L3MBTL1RAB9ACYP1A2 | |
| SCHEMBL17243395 | 0.77 | WNT3A (0.51) | WNT3ASMN1; SMN2L3MBTL1PORCN | |
| SCHEMBL248694 | 0.77 | HPGDS (0.47) | WNT3ASMN1; SMN2L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL17243392 | 0.76 | WNT3A (0.51) | WNT3ASMN1; SMN2PORCNCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | WNT3A 1/4885SMN1; SMN2 4423/4885L3MBTL1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.